Fennec Pharmaceuticals Inc. (FENC) financial statements and ratios from SEC XBRL: revenue $44.64M (TTM), net margin -21.8%, revenue growth -6.1% YoY, P/E 227.9. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $44.64M |
| Net Margin | -21.8% |
| Revenue Growth (YoY) | -6.1% |
| EPS Growth (YoY) | 1600.0% |
| P/E Ratio | 227.9 |
| EV / EBITDA | 270.7 |
| Price / Book | 9.33 |
| Price / Sales | 6.54 |
| Altman Z-Score | 3.41 (safe) |
| Sector P/E (Healthcare) | 21.7 |
FENC overview · FENC earnings · FENC KPIs · FENC investor relations · FENC ownership · FENC peers · FENC filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.